The purpose of this study is to determine if Karenitecin (BNP1350) is effective in the treatment of brain tumors.

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

• Confirmed diagnosis of a newly diagnosed glioblastoma multiforme or recurrent/progressive glioblastoma multiforme, anaplastic astrocytoma, or anaplastic oligodendroglioma.
• Evidence of measurable recurrent or residual primary CNS neoplasm.
• An interval of at least 3 weeks between prior surgical resection or 6 weeks between prior radiotherapy or chemotherapy, and enrollment on this protocol unless there is unequivocal evidence of tumor progression after surgery, radiotherapy, or chemotherapy.
• Hematocrit > 29%, ANC > 1,500, platelets > 125,000
• Serum creatinine < 1.5 mg/dl, BUN < 25 mg/dl, serum SGOT and bilirubin < 1.5 times upper limit of normal
• Negative pregnancy test for female patients